Day: July 9, 2025

Not for distribution to U.S. newswire services or dissemination in the United States Vancouver, British Columbia, July 09, 2025 (GLOBE NEWSWIRE) — Surge Copper Corp. (TSXV: SURG) (OTCQB: SRGXF) (Frankfurt: G6D2) (“Surge” or the “Company”) is pleased to announce that, due to strong investor demand, it has upsized its previously announced non-brokered equity financing (see July 7, 2025 press release) from approximately $6.4 million to up to $10.4 million (the “Offering”). The Offering is fully subscribed, with strong participation from both new and existing investors. The Offering will now consist of the following components:LIFE Offering: A non-brokered private placement of up to 19.2 million common shares (the “Common Shares”) at a price of $0.175 per share for gross proceeds of up to $3.4 million (the “LIFE Offering”). This...

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) — (NASDAQ: SQFT; SQFTP; SQFTW) Presidio Property Trust, Inc. (“Presidio” or the “Company”), an internally managed, diversified real estate investment trust (“REIT”) announced that in the second quarter of 2025, through subsidiary and affiliate entities, have sold seven homes for a total of approximately $3.5 million. These homes were purchased between 2020 and 2023 with a total acquisition price of approximately $3.2 million. Additionally, we acquired 10 homes totaling approximately $5.2 million, located in Texas, Alabama and Tennessee. Model homes account for approximately 34% of our net real estate assets and approximately 24% of our rental revenue. We wholly own 68 of the 87 model homes in our portfolio as of June 30, 2025. “In the first half of the year, our team has done an outstanding...

Figure: 1Palisade Bio, Inc. Appoints Emil Chuang, MB BS FRACP to its Board of DirectorsVeteran clinical leader with successful track record and experience to help guide the Company’s clinical strategy in Fibrostenotic Crohn’s Disease and Ulcerative Colitis Carlsbad, CA, July 09, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Emil Chuang, MB BS FRACP to its Board of Directors.Dr. Chuang is a pediatric gastroenterologist with nearly 25 years of pharmaceutical and clinical experience spanning large pharma, biotech, therapeutics, medical nutrition, and diagnostics. His expertise spans from...

The Company expects to receive revenues, for the first time, through its collaboration with Elbit from initial sales of the “Birds of Prey” stabilized weapons drone system FT. LAUDERDALE, FL, July 09, 2025 (GLOBE NEWSWIRE) — Duke Robotics Corp. (OTCQB: DUKR) (“Duke Robotics” or the “Company“), a leader in advanced robotics technology and autonomous drone solutions, today announced that it expects to receive initial revenues from royalties for sales of the “Birds of Prey” stabilized weapons drone systems through its collaboration with Elbit Land Systems Ltd (“Elbit”). The stabilized weapons drone system, which has been marketed and deployed by Elbit under the brand name “Birds of Prey”, features proprietary technology that enables precise remote operations via an unmanned aerial platform, designed...

HIAB CORPORATION, PRESS RELEASE, 9 JULY 2025 AT 15:30 PM (EEST) Hiab’s half-year financial report January–June 2025 to be published on Wednesday, 23 July 2025 Hiab Corporation will publish its half-year financial report January–June 2025 on Wednesday, 23 July 2025 at approximately 8:00 a.m. EEST. The report will be available at www.hiabgroup.com after publication. A live international telephone conference for analysts, investors and media will be arranged on the publishing day at 10:00 a.m. EEST. The event will be held in English. The report will be presented by President and CEO Scott Phillips and CFO Mikko Puolakka. The presentation material will be available at www.hiabgroup.com by the latest 9:30 a.m. EEST. To ask questions during the conference, please register via the following link:
https://palvelu.flik.fi/teleconference/?id=50052228....

Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204’s Innovative Delivery System; Company is Currently Conducting Additional Studies into New and Previously Untested KRAS Mutation with Results expected in the Near Future Grand Cayman, Cayman Islands, July 09, 2025 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new positive preclinical data demonstrating SIL204’s significant efficacy in human lung cancer cell lines. The Company is also pleased to announce that it is in the process of conducting a new study examining the efficacy of SIL204 on a new previously untested KRAS mutation,...

Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidates Iambic to receive up to $25 million through a combination of upfront and expected near-term performance-based milestone payments for services related to Revolution Medicines’ access to Iambic’s industry-leading NeuralPLexer model for protein structure predictionREDWOOD CITY, Calif. and SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing  targeted therapies for patients with RAS-addicted cancers, and Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced a technology and research collaboration to pursue novel drug...

Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief Medical Officer REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced a corporate reorganization to extend its cash runway, including a workforce reduction of approximately 50%. As part of the reorganization, Edwin Tucker, M.D., is departing as Jasper’s Chief Medical Officer, and Daniel Adelman, M.D., a member of Jasper’s Scientific...

HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a Bitcoin First Company and global leader in sustainable energy management, today announced the successful deployment of 3,570 Bitmain S19 XP 140T Bitcoin mining machines at facilities located in Asuncion, Paraguay, thereby boosting the Company’s operational capacity to 750 petahash per second (PH/s) across multiple mining locations. This deployment underscores KULR’s dual acquisition strategy of both mining Bitcoin and purchasing it on the open market. By leveraging a “buy-or-mine” flexibility, KULR intends to build its BTC holdings more efficiently rather than relying on a single method of BTC accumulation. Michael Mo, KULR’s CEO, commented on the news, “Bitcoin has outpaced every...

VANCOUVER, Canada, July 09, 2025 (GLOBE NEWSWIRE) — Sonoro Gold Corp. (TSXV: SGO | OTCQB: SMOFF | FRA: 23SP) (“Sonoro” or the “Company”) is pleased to provide an update on the status of the Environmental Impact Statement, or Manifestacion de Impacto Ambiental (“MIA”) for its Cerro Caliche gold project in Sonora, Mexico. The Company has submitted a revised MIA to the Mexican federal permitting authority, Secretaria de Medio Ambiente y Recursos Naturales (“SEMARNAT”) to optimize the project’s footprint and enhance social and environmental stewardship. The revised MIA was initially submitted in February 2025 and supersedes the prior MIA submitted in May 2022. Revisions to the MIA, including enhancing the mine plan and undertaking additional environmental baseline studies and socio-economic assessments, reflect the Company’s commitment...